Abstract | OBJECTIVES: METHODS: Baseline patient characteristics and treatment effect data from the recent 'INITIATE' clinical trial served as input to a peer-reviewed, validated Markov/Monte-Carlo simulation model. INITIATE demonstrated improvements in HbA1c favouring BIAsp 70/30 vs. glargine (-0.43%; p < 0.005) and greater efficacy in reaching glycaemic targets among patients poorly controlled on OAD therapy. Effects on life expectancy (LE), quality-adjusted life expectancy (QALE), cumulative incidence of diabetes-related complications and direct medical costs (2004 USD) were projected over 35 years. Clinical outcomes and costs were discounted at a rate of 3.0% per annum. Sensitivity analyses were performed. RESULTS: Improvements in glycaemic control were projected to lead to gains in LE (0.19 +/- 0.24 years) and QALE (0.19 +/- 0.17 years) favouring BIAsp 70/30 vs. glargine. Treatment with BIAsp 70/30 was also associated with reductions in the cumulative incidences of diabetes-related complications, notably in renal and retinal conditions. The incremental cost-effectiveness ratio was $46 533 per quality-adjusted life year gained with BIAsp 70/30 vs. glargine (for patients with baseline HbA1c >/= 8.5%, it was $34 916). Total lifetime costs were compared to efficacy rates in both arms as a ratio, which revealed that the lifetime cost per patient treated successfully to target HbA1c levels of <7.0% and </= 6.5% were $80 523 and $93 242 lower with BIAsp 70/30 than with glargine, respectively. CONCLUSIONS: Long-term treatment with BIAsp 70/30 was projected to be cost-effective for patients with type 2 diabetes insufficiently controlled on OADs alone compared to glargine. Treatment with BIAsp 70/30 was estimated to represent an appropriate investment of healthcare dollars in the management of type 2 diabetes.
|
Authors | J A Ray, W J Valentine, S Roze, L Nicklasson, D Cobden, P Raskin, A Garber, A J Palmer |
Journal | Diabetes, obesity & metabolism
(Diabetes Obes Metab)
Vol. 9
Issue 1
Pg. 103-13
(Jan 2007)
ISSN: 1462-8902 [Print] England |
PMID | 17199725
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biphasic Insulins
- Glycated Hemoglobin A
- Hypoglycemic Agents
- Insulin
- Insulin, Long-Acting
- insulin aspart, insulin aspart protamine drug combination 30:70
- Insulin Glargine
- Insulin, Isophane
- Insulin Aspart
|
Topics |
- Administration, Oral
- Adult
- Aged
- Biphasic Insulins
- Cost-Benefit Analysis
- Diabetes Complications
(economics, prevention & control)
- Diabetes Mellitus, Type 2
(blood, complications, drug therapy, economics)
- Epidemiologic Methods
- Female
- Glycated Hemoglobin
(metabolism)
- Health Care Costs
(statistics & numerical data)
- Humans
- Hypoglycemic Agents
(economics, therapeutic use)
- Insulin
(analogs & derivatives, economics, therapeutic use)
- Insulin Aspart
- Insulin Glargine
- Insulin, Isophane
- Insulin, Long-Acting
- Male
- Middle Aged
- Treatment Failure
- Treatment Outcome
|